Posted by Michael Wonder on 06 Feb 2025
Acrivon Therapeutics announces FDA has granted breakthrough device designation for ACR-368 OncoSignature assay for endometrial cancer
5 February 2025 - The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s on-going, registrational-intent, multi-centre Phase 2b trial of ACR-368 in patients with endometrial cancer and other tumour types.
Acrivon Therapeutics announced the US FDA has granted breakthrough device designation for the ACR-368 OncoSignature assay, a multiplex immunofluorescence assay for the identification of endometrial cancer patients who may benefit from ACR-368 treatment.
